Research programme: cancer therapies - CytoGenix

Drug Profile

Research programme: cancer therapies - CytoGenix

Alternative Names: Cancer therapies research programme -CytoGenix

Latest Information Update: 02 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CytoGenix
  • Class Gene therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Cancer metastases

Most Recent Events

  • 23 Jan 2004 Cytogenix and Baylor College of Medicine have entered into an agreement to co-develop a ssDNA expression vector administered via aerosol delivery in the US for metastatic lung cancer
  • 23 Jan 2004 Preclinical trials in Cancer metastases in USA (unspecified route)
  • 22 Oct 2003 This programme is available for licensing (http://www.cytogenix.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top